Highlights
KLSE: SCOMNET (0001)       SUPERCOMNET TECHNOLOGIES BHD ACE : Health Care
Last Price Today's Change   Day's Range   Trading Volume
1.88   0.00 (0.00%)  0.00 - 0.00  0
Analyze this stock with MQ Trader system

Financials


Market Cap: 1,273 Million

Market Cap 1,273 Million
NOSH 677 Million

Latest Audited Result:  31-Dec-2019

Latest Audited Result: 31-Dec-2019
Announcement Date 30-Jun-2020
Next Audited Result: 31-Dec-2020
Est. Ann. Date: 30-Jun-2021
Est. Ann. Due Date: 29-Jun-2021

Latest Quarter:  30-Sep-2020 [#3]

Latest Quarter: 30-Sep-2020 [#3]
Announcement Date 30-Nov-2020
Next Quarter: 31-Dec-2020
Est. Ann. Date: 27-Feb-2021
Est. Ann. Due Date: 01-Mar-2021
QoQ | YoY   -13.36%  |    -0.54%

Annual (Unaudited) ( EPS: 2.78, P/E: 67.63 )

Revenue | NP to SH 122,969  |  18,821
RPS | P/RPS 18.16 Cent  |  10.35
EPS | P/E | EY 2.78 Cent  |  67.63  |  1.48%
DPS | DY | Payout % 1.42 Cent  |  0.76%  |  51.25%
NAPS | P/NAPS 0.30  |  6.19
YoY   54.61%
NP Margin | ROE 15.31%  |  9.15%
F.Y. | Ann. Date 31-Dec-2019  |  27-Feb-2020

T4Q Result ( EPS: 2.92, P/E: 64.40 )

Revenue | NP to SH 122,463  |  19,766
RPS | P/RPS 18.09 Cent  |  10.39
EPS | P/E | EY 2.92 Cent  |  64.40  |  1.55%
DPS | DY | Payout % 1.47 Cent  |  0.78%  |  50.52%
NAPS | P/NAPS 0.33  |  5.63
QoQ | YoY   -0.14%  |    21.42%
NP Margin | ROE 16.14%  |  8.74%
F.Y. | Ann. Date 30-Sep-2020  |  30-Nov-2020

Annualized Result ( EPS: 2.99, P/E: 62.78 )

Revenue | NP to SH 120,089  |  20,274
RPS | P/RPS 17.74 Cent  |  10.60
EPS | P/E | EY 2.99 Cent  |  62.78  |  1.59%
DPS | DY | Payout % -
NAPS | P/NAPS -
QoQ | YoY   0.88%  |    6.64%
NP Margin | ROE 16.88%  |  8.96%
F.Y. | Ann. Date 30-Sep-2020  |  30-Nov-2020



Business Performance

Business Performance (By Quarter)

Trailing 4 Quarters Trailing 8 Quarters
Available Quarters 4 Quarters 8 Quarters
Continuous Quarters Of Revenue Growth 1 / 4 25.00% 1 / 8 12.50%
Total Positive Profit Years 4 / 4 100.00% 8 / 8 100.00%
Continuous Quarters Of Positive Profit 4 / 4 100.00% 8 / 8 100.00%
Continuous Quarters Of Profit Growth 0 / 4 0.00% 0 / 8 0.00%
Continuous Quarters Of Adjusted EPS Growth 0 / 4 0.00% 0 / 8 0.00%
Total Dividend Years 1 / 4 25.00% 2 / 8 25.00%
Continuous Quarters Of Dividend 1 / 4 25.00% 1 / 8 12.50%
Continuous Quarters Of Dividend Growth 0 / 4 0.00% 0 / 8 0.00%
Continuous Quarters Of Adjusted Dps Growth 1 / 4 25.00% 1 / 8 12.50%
Average ROE 2.30% 2.24%
Average Net Profit Margin 16.73% 15.20%

Business Performance (By Year)

Last 5 Financial Years Last 10 Financial Years
Available Years 5 Years 10 Years
Continuous Years Of Revenue Growth 3 / 5 60.00% 3 / 10 30.00%
Total Positive Profit Years 5 / 5 100.00% 9 / 10 90.00%
Continuous Years Of Positive Profit 5 / 5 100.00% 9 / 10 90.00%
Continuous Years Of Profit Growth 3 / 5 60.00% 3 / 10 30.00%
Continuous Years Of Adjusted EPS Growth 3 / 5 60.00% 3 / 10 30.00%
Total Dividend Years 2 / 5 40.00% 3 / 10 30.00%
Continuous Years Of Dividend 1 / 5 20.00% 1 / 10 10.00%
Continuous Years Of Dividend Growth 0 / 5 0.00% 0 / 10 0.00%
Continuous Years Of Adjusted Dps Growth 1 / 5 20.00% 1 / 10 10.00%
Average ROE 7.39% 5.52%
Average Net Profit Margin 10.57% 7.29%

Key Result

Key Result

T4Q Annualized Annual (Unaudited) Last 10 FY Average Last 5 FY Average
Revenue 122,463 120,089 122,969 47,329 62,211
NP to SH 19,766 20,274 18,821 4,560 7,782
Dividend 9,985 13,313 9,645 1,183 2,123
Adjusted EPS 2.92 2.99 2.78 0.67 1.15
Adjusted DPS 1.47 1.97 1.42 0.18 0.31

NP to SH = Net Profit Attributable to Shareholder, EPS = Earning Per Share, DPS = Dividend Per Share

All figures in '000 unless specified.

EPS & DPS's figures in Cent.


Growth

Growth (By Quarter)

LQ QoQ LQ YoY CQ YoY LQ vs Average of T4Q LQ vs Average of T8Q
Revenue 56.28% 7.79% -0.56% 23.33% 25.73%
NP to Owner -13.36% -0.54% 6.64% 4.36% 14.46%
Dividend 0.00% 0.00% 3.53% 300.00% 306.93%
Adj. EPS -13.36% -0.54% 6.64% 4.36% 14.46%
Adj. DPS 0.00% 0.00% 3.53% 300.00% 306.93%

LQ = Latest Quarter, CQ = Cumulative Quarter, T4Q = Trailing 4 Quarters, T8Q = Trailing 8 Quarters, QoQ = Quarter on Quarter, YoY = Year on Year

Growth (By Year)

T4Q vs LFY T4Q vs AL5FY T4Q vs AL10FY AQR vs LFY AQR vs AL5FY AQR vs AL10FY LFY YoY LFY vs AL5FY LFY vs AL10FY
Revenue -0.41% 96.85% 158.75% -2.34% 93.03% 153.73% 39.28% 97.66% 159.82%
NP to Owner 5.02% 153.98% 333.45% 7.72% 160.52% 344.60% 54.61% 141.84% 312.72%
Dividend 3.53% 370.24% 743.63% - % - % - % 0.00% 354.22% 714.89%
Adj. EPS 5.02% 153.98% 333.45% 7.72% 160.52% 344.60% 54.61% 141.84% 312.72%
Adj. DPS 3.53% 370.24% 743.63% - % - % - % 0.00% 354.22% 714.89%

T4Q = Trailing 4 Quarters, T8Q = Trailing 8 Quarters, AL5FY = Average of Last 5 Financial Years, AL10FY = Average of Last 10 Financial Years, LFY = Latest Financial Year AQR = Annualized Quarter Result, YoY = Year on Year

Trade this stock with 3 x trading limit. Find out more.
  7 people like this.
 
Mr.Sm Invest123 Close at 2.06 not bad not bad. I am hold tight
30/11/2020 8:55 PM
jazzkhor I guess I need to learn how to be patient on stock investment. Can't wait to see the price go up.
01/12/2020 2:35 PM
gohfredd Volatility of stock is normal and sometimes it goes down... no worries as long as the company with good fundamentals and debt free. When they improved their results by next few QR, it will reflect in their stock prices :>
01/12/2020 5:40 PM
tiknuhc scomnet is good counter. WIll vaccine news lower future profit for scomnet???
02/12/2020 11:24 PM
bigearl Not much movement after QR. Guess is time to hold till next QR.
03/12/2020 9:52 AM
gohfredd tiknuhc.. this company is dealing with all types of cables ... not related to Covid or vaccines.. go to the company website and pick up the information. Nursing related cables should be the key products to bring them higher profit. July 20 got approval for their new products from FDA... to help patients with cardiovascular disease.. do your homework before investing more ya :>>
03/12/2020 5:49 PM
arlaxeat https://www.google.com/amp/s/simplywall.st/stocks/my/capital-goods/klse-scomnet/supercomnet-technologies-berhad-shares/news/could-the-market-be-wrong-about-supercomnet-technologies-ber/amp
03/12/2020 6:06 PM
gohfredd Thanks arlaxeat for the article.. indeed is interesting enough for those who are interested about to buy this counter :>
03/12/2020 8:06 PM
bigearl Any take on this?
04/12/2020 10:09 AM
jazzkhor feeling to cut lost. wasting time
04/12/2020 10:17 AM
bigearl I think I still have faith on this counter. Future wise they are healthy. I think this latest QR is due to the FOREX thingy.
04/12/2020 12:49 PM
jazzkhor My gut feel also good counter. But seeing this dropping. My faith have drop
04/12/2020 3:54 PM
Shashe Be patient guys... good counter. Will go up.
04/12/2020 11:48 PM
jazzkhor no good no good.
07/12/2020 9:43 AM
bigearl Wahhh dropping further
07/12/2020 10:30 AM
gemfinder today how many waterfish trapped? kikiki
07/12/2020 10:39 AM
jazzkhor strong company but no people support the company. is that why drop in short term? but if it is a good fundamental company, long term the price will shoot triple or even more? am i right?
07/12/2020 11:21 AM
ZacChuinn91 Drop below the support level of RM1.90. Finger crossed it will rebound back later this afternoon
07/12/2020 1:54 PM
tiknuhc still holding. but honestly a bit worried. this counter following the trend of the other glove and healthcare counters.
07/12/2020 5:16 PM
bigearl I am holding and worried at the same time.
07/12/2020 6:08 PM
bigearl MONEY TALK
Supercomnet Technologies (SCT MK)
Staging For A Stronger Comeback
3Q20 was an uneventful quarter dragged by forex losses, cost overrun and higher
raw material cost for a new project start-up. That said, we understand these were just
temporary setbacks which should not recur after the improvement in learning curve.
Scomnet is staging for a stronger comeback,backed by strong orderbook visibility
from its broad spectrum of key clients. Maintain BUY with target price of RM2.40.
RESULTS HIGHLIGHTS
 A temporary blip. Supercomnet Technologies (Scomnet) recorded a dismal 3Q20 core
net profit of RM5.5m (+3.5% qoq, +19.6 yoy), bringing 9M20 core net profit to Rm13.8m
which only made up 51% of our full-year estimate. Nevertheless, 3Q20 revenue grew 7.8%
yoy to RM37.8m, backed by stronger sales from both the medical and automobile
segments.
 Bottom-line shortfall and margin downtick on exceptional outflows. Despite stronger
revenue in the quarter, we noticed a plunge in net margin that impacted the bottom-line
numbers. On a yoy basis, the slight decline in net margin (-1.1% yoy) was mainly due to
labour and raw material cost overrun, driven by one of its key medical clients’ urgent
demand surge for its endoscope cable. The rejection rate of this product spiked during the
quarter, causing higher wastage of raw materials as well as overtime shifts to fulfil the
overwhelming demand. All that being said, we understand that all these are non-recurring
items as management has taken the necessary steps to achieve better efficiency with cost
normalisation expected from 4Q20 onwards.
 More clarity on SMP’s robust orderbook guidance... Our recent channel check with
management revealed that orderbook volume for Scomnet’s medical segment,
Supercomal Medical Products (SMP), remains strong, with orderbook visibility until 2Q21
and 1Q22 for key clients – customer E and customer A respectively. Note that both
customers made up about 90% of SMP’s revenue in 2019.
 …but slight disruption from COVID-19 impact. Due to the COVID-19 disruption, there
are some reduction in orders volume from its customer M. Vis-à-vis the decent sales
projection from this customer which could boost its earnings by 25% from 3Q20 onwards,
the mass production has been delayed on COVID-19 disruption. Nevertheless, the
shortfall of revenue contribution from this customer was partially offset by stronger demand
from customer A and customer E.
07/12/2020 6:25 PM
bigearl  Multi-pronged catalysts to sustain supercharged growth beyond 2021. We believe
Scomnet will emerge as one of the most prominent global healthcare proxies in Malaysia
and poised to deliver explosive earnings in FY21. This will be mainly driven by: a) resilient
earnings visibility from its strong medical orderbooks on hand; b) incremental revenue from
new medical products (D’Clot Catheter, Colonoscopy GI and Gastroscopy GI which will begin
mass production in 1Q21; customer M’s D’Clot and new clients’ blood clotting product); c)
near-term capacity expansion to fulfil explosive demand for medical segment’s products; d)
significant contribution from new automobile client – customer P from 3Q21 onwards; and e)
transfer to healthcare sector and mainboard listing which could catalyse a potential valuation
rerating.
 Maintain BUY with a target price of RM2.40. Post meeting, we have trimmed our 2020-
21 revenue forecasts by 12% and 10% respectively to reflect lower contributions from
Mermaid Medical and PSA on the slower orderbook projections. We are also assuming a
full conversion of existing warrants into our valuations, factoring in share base of 857.3m
shares and theoretical cash increment of RM140m. In terms of valuation (refer RHS
valuation table), we have pegged our target price to 35x 2021F PE, its 3-year mean and at
a discount to Bursa Malaysia Healthcare Index of 43x.
INVESTMENT HIGHLIGHTS
 Medical segment: SMP will see its full potential in FY21. SMP’s growth will be fuelled
by several new products which are poised for commercial production from 2021 onwards.
a) For customer A, the spotlight will be on its Colonoscopy GI, Gastrocopy GI and
Duodenoscopy GI which is expected to contribute about 15-20% of incremental group
revenue from 2021 onwards. The overwhelming demand for its endoscopy cables,
which has seen a tremendous sales leap of several folds compared to pre-MCO
levels, will also significantly enhance earnings.
b) For customer E, SMP will continue to benefit from the expansion of medical
orderbook with organic yoy growth of at least 10-16% for its existing products, while
there are also about seven projects with customer E on hand.
c) For customer M, the mass production of its D’Clot HD Catheter has been pushed
back due to the delays in product training processes amid COVID-19 disruptions.
That said, this is just a temporary setback and production should be able to start
immediately once the doctors are able to conduct physical training and complete the
production requirements.
d) We also understand that SMP has secured a new client with a prominent new blood
clotting product for dialysis. While Scomnet recently presented the product to FDA in
Los Angeles, the approval results should be announced in Feb/Mar 21. Notably, the
US Navy Force has signed an agreement to receive supply of this blood clotting
product. We believe this product can contribute positively to SMP’s earnings as early
as 2Q21 next year immediately after FDA approval, given that SMP has already
allocated the facilities and equipment required for commercial production.
 Automobile segment: Growth trajectory from customer P. The emergence of
Supercomal Advanced Cables’ (SAC) latest key customer P will enhance the growth of
Scomnet’s automobile segment. The agreement from this customer, which allows SAC to
supply wire harnessing and fuel tanks (higher margin), is expected to contribute about 20-
30% incremental revenue to SAC’s current revenue base in 2021, with subsequent years
to see higher revenue contributions. 2021’s earnings growth will be backed by new
revenue streams from this customer. We also understand that customer P has recently
put in another RM6.6m capex into SAC to purchase wire harness and fuel tank
production equipment.
07/12/2020 6:25 PM
tiknuhc @bigearl the above investment research report is from which fundhouse?
07/12/2020 9:55 PM
bigearl UOB KAY HIAN. It's in a PDF don't know how to share it.
07/12/2020 9:57 PM
Mr.Sm Invest123 Rakuten recommends these stocks for 2021 - http://www.theedgemarkets.com/article/rakuten-recommends-these-stocks-2021 (Share from StockHunter)
07/12/2020 10:05 PM
tiknuhc the rakuten recommendation is from an earlier old report that didnt take into account the latest lacklustre earning.
08/12/2020 12:35 AM
bigearl For real?
08/12/2020 12:50 AM
bigearl So all these newspaper are lies?
08/12/2020 12:50 AM
tiknuhc not lies but they just take from old reports? the rakuten report is a September report. see link below with the TP 2.68. i'm sure if they see the new quarterly earningsm they will adjust the TP

https://klse.i3investor.com/blogs/rakuten/2020-09-07-story-h1513373765-Supercomnet_Technologies_Supercharged_Growth_Continues.jsp
08/12/2020 1:03 AM
jazzkhor i really hope rakuten aim scomnet TP 2.68.

ever since i bought scomnet keep on falling. :(
08/12/2020 9:47 AM
bigearl They are focusing on next year.
08/12/2020 9:58 AM
gohfredd Jazzkhor... this is not a goreng counter ... read some good comments from this forum, the price will automatically adjust up accordingly once the results improved. I will hold this counter for at least 6 more months ...:>
08/12/2020 1:36 PM
Loop37 Closed with hammer today...good sign
08/12/2020 4:44 PM
Jolly This counter anytime can close RM2.00 soon ..
08/12/2020 6:14 PM
NPRA1985 UAE says Sinopharm vaccine has 86% efficacy against COVID-19

DUBAI (Reuters) - An experimental coronavirus vaccine developed by China’s Sinopharm has 86% efficacy against the virus, the United Arab Emirates health ministry said on Wednesday, citing an interim analysis of a human trial underway there.

The Gulf Arab state in July started Phase 3 clinical trials of the vaccine, developed by Beijing Institute of Biological Product, a unit of Sinopharm’s China National Biotec Group (CNBG). In September, the UAE approved its emergency use for certain groups.

The analysis also shows “99% seroconversion rate of neutralizing antibody and 100% effectiveness in preventing moderate and severe cases of the disease”, the ministry said in a statement carried by the state news agency.

“The analysis shows no serious safety concerns,” it said.

It also said it had officially registered the vaccine, without elaborating, and that 31,000 volunteers across 125 nationalities participated in the UAE trial.

https://www.reuters.com/article/health-coronavirus-emirates/update-1-uae-says-sinopharm-vaccine-has-86-efficacy-against-covid-19-idUSL1N2IP09V
09/12/2020 3:38 PM
NPRA1985 United Arab Emirates Claims China’s Sinopharm Vaccine Is 100% Effective At Preventing Moderate And Severe Covid-19

TOPLINE The experimental vaccine developed by China National Pharmaceutical Group, also known as Sinopharm, is 86% effective at preventing Covid-19 infection and 100% effective at preventing severe and moderate disease, health officials from the United Arab Emirates announced Wednesday, although with scarce detail provided about the trial.

The UAE health ministry cited an interim analysis of a late-stage clinical trial involving 31,000 volunteers as the source of its information, though neither they nor Sinopharm provided any data from the trial to validate the claims such as how many participants were infected or how many actually received the vaccine.

The ministry said “no serious safety concerns” were observed, though, again, no information on side effects was provided.

The ministry said the announcement is a “significant vote of confidence by the UAE’s health authorities in the safety and efficacy of this vaccine.”

The ministry added that it had officially registered the vaccine at the request of the manufacturer, which it says could eventually lead to the shot’s widespread authorization.

https://www.forbes.com/sites/roberthart/2020/12/09/united-arab-emirates-claims-chinas-sinopharm-vaccine-is-100-effective-at-preventing-moderate-and-severe-covid-19/?sh=2a60fb42595c
09/12/2020 10:40 PM
BigPortfolio NPRA is sozai
21/12/2020 12:35 PM
t_nike2002 Vaccine availability does Not have any major impact on scomnet. Pls go and read what Scomnet produces on their website.

Scomnet performance will thrive even with vaccine and post covid..
28/12/2020 10:55 AM
Mr.Sm Invest123 https://www.klsescreener.com/v2/news/view/773081
02/01/2021 6:18 PM
Mr.Sm Invest123 Supercomnet reclassified under healthcare sector - http://www.theedgemarkets.com/article/supercomnet-reclassified-under-healthcare-sector (Share from StockHunter)
06/01/2021 6:08 PM
Mr.Sm Invest123 https://www.klsescreener.com/v2/news/view/774667
06/01/2021 6:17 PM
jun1920 anyone still holding from rm2?
06/01/2021 9:14 PM
Shashe This counter so quiet.
Is it a good news that they classified as health care company?
07/01/2021 12:00 AM
Plantermen Business diversified and moved into medical healthcare related segments
07/01/2021 7:49 PM
Newbie318 Supercomnet Technologies (SCT MK) 
Staging For A Stronger Comeback 
3Q20 was an uneventful quarter dragged by forex losses, cost overrun and higher 
raw material cost for a new project start-up. That said, we understand these were just 
temporary setbacks which should not recur after the improvement in learning curve. 
Scomnet is staging for a stronger comeback,backed by strong orderbook visibility 
from its broad spectrum of key clients. Maintain BUY with target price of RM2.40. 
RESULTS HIGHLIGHTS 
 A temporary blip. Supercomnet Technologies (Scomnet) recorded a dismal 3Q20 core 
net profit of RM5.5m (+3.5% qoq, +19.6 yoy), bringing 9M20 core net profit to Rm13.8m 
which only made up 51% of our full-year estimate. Nevertheless, 3Q20 revenue grew 7.8% 
yoy to RM37.8m, backed by stronger sales from both the medical and automobile 
segments. 
 Bottom-line shortfall and margin downtick on exceptional outflows. Despite stronger 
revenue in the quarter, we noticed a plunge in net margin that impacted the bottom-line 
numbers. On a yoy basis, the slight decline in net margin (-1.1% yoy) was mainly due to 
labour and raw material cost overrun, driven by one of its key medical clients’ urgent 
demand surge for its endoscope cable. The rejection rate of this product spiked during the 
quarter, causing higher wastage of raw materials as well as overtime shifts to fulfil the 
overwhelming demand. All that being said, we understand that all these are non-recurring 
items as management has taken the necessary steps to achieve better efficiency with cost 
normalisation expected from 4Q20 onwards. 
 More clarity on SMP’s robust orderbook guidance... Our recent channel check with 
management revealed that orderbook volume for Scomnet’s medical segment, 
Supercomal Medical Products (SMP), remains strong, with orderbook visibility until 2Q21 
and 1Q22 for key clients – customer E and customer A respectively. Note that both 
customers made up about 90% of SMP’s revenue in 2019. 
 …but slight disruption from COVID-19 impact. Due to the COVID-19 disruption, there 
are some reduction in orders volume from its customer M. Vis-à-vis the decent sales 
projection from this customer which could boost its earnings by 25% from 3Q20 onwards, 
the mass production has been delayed on COVID-19 disruption. Nevertheless, the 
shortfall of revenue contribution from this customer was partially offset by stronger demand 
from customer A and customer E.

07/12/2020 6:25 PM



bigearl  Multi-pronged catalysts to sustain supercharged growth beyond 2021. We believe 
Scomnet will emerge as one of the most prominent global healthcare proxies in Malaysia 
and poised to deliver explosive earnings in FY21. This will be mainly driven by: a) resilient 
earnings visibility from its strong medical orderbooks on hand; b) incremental revenue from 
new medical products (D’Clot Catheter, Colonoscopy GI and Gastroscopy GI which will begin 
mass production in 1Q21; customer M’s D’Clot and new clients’ blood clotting product); c) 
near-term capacity expansion to fulfil explosive demand for medical segment’s products; d) 
significant contribution from new automobile client – customer P from 3Q21 onwards; and e) 
transfer to healthcare sector and mainboard listing which could catalyse a potential valuation 
rerating. 
 Maintain BUY with a target price of RM2.40. Post meeting, we have trimmed our 2020- 
21 revenue forecasts by 12% and 10% respectively to reflect lower contributions from 
Mermaid Medical and PSA on the slower orderbook projections. We are also assuming a 
full conversion of existing warrants into our valuations, factoring in share base of 857.3m 
shares and theoretical cash increment of RM140m. In terms of valuation (refer RHS 
valuation table), we have pegged our target price to 35x 2021F PE, its 3-year mean and at 
a discount to Bursa Malaysia Healthcare Index of 43x. 
INVESTMENT HIGHLIGHTS 
 Medical segment: SMP will see its full potential in FY21. SMP’s growth will be fuelled 
by several new products which are poised for com
07/01/2021 8:00 PM
Newbie318 on from 2021 onwards. 
a) For customer A, the spotlight will be on its Colonoscopy GI, Gastrocopy GI and 
Duodenoscopy GI which is expected to contribute about 15-20% of incremental group 
revenue from 2021 onwards. The overwhelming demand for its endoscopy cables, 
which has seen a tremendous sales leap of several folds compared to pre-MCO 
levels, will also significantly enhance earnings. 
b) For customer E, SMP will continue to benefit from the expansion of medical 
orderbook with organic yoy growth of at least 10-16% for its existing products, while 
there are also about seven projects with customer E on hand. 
c) For customer M, the mass production of its D’Clot HD Catheter has been pushed 
back due to the delays in product training processes amid COVID-19 disruptions. 
That said, this is just a temporary setback and production should be able to start 
immediately once the doctors are able to conduct physical training and complete the 
production requirements. 
d) We also understand that SMP has secured a new client with a prominent new blood 
clotting product for dialysis. While Scomnet recently presented the product to FDA in 
Los Angeles, the approval results should be announced in Feb/Mar 21. Notably, the 
US Navy Force has signed an agreement to receive supply of this blood clotting 
product. We believe this product can contribute positively to SMP’s earnings as early 
as 2Q21 next year immediately after FDA approval, given that SMP has already 
allocated the facilities and equipment required for commercial production. 
 Automobile segment: Growth trajectory from customer P. The emergence of 
Supercomal Advanced Cables’ (SAC) latest key customer P will enhance the growth of 
Scomnet’s automobile segment. The agreement from this customer, which allows SAC to 
supply wire harnessing and fuel tanks (higher margin), is expected to contribute about 20- 
30% incremental revenue to SAC’s current revenue base in 2021, with subsequent years 
to see higher revenue contributions. 2021’s earnings growth will be backed by new 
revenue streams from this customer. We also understand that customer P has recently 
put in another RM6.6m capex into SAC to purchase wire harness and fuel tank 
production equipment.

07/12/2020 6:25 PM
07/01/2021 8:02 PM
Plantermen Good article on supercomnet medical related business.
08/01/2021 7:12 AM
azee RHB Research: Lee said the 5G hype is just getting started.
https://klse.i3investor.com/blogs/IR4Revolution/2020-12-30-story-h1538458939-IR4_Beneficiary_ELSOFT_INARI_ISTONE_MPI_UNISEM.jsp
08/01/2021 12:34 PM
jun1920 warrant fly but mother stagnant...
08/01/2021 1:28 PM
Toplove888 Still steady Abit boring no movement this few weeks... price still vry stable need to put more gas to 2.00 above
20/01/2021 6:29 PM